An increased understanding of the genomic and molecular underpinnings of cancer pathogenesis and their exploitation in the development of targeted therapies has revolutionized the treatment of many cancer types including BRAF-mutant melanoma, HER2-amplified breast cancer, and non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements.
Biomarkers are critical for the personalization of therapy in oncology. It is quite clear that all therapies, no matter how potent, will require some personalization to reach their maximum effect.
As discussed in the main article in this publication, the use of biomarkers has revolutionized the treatment of many types of cancer in a very personalized way, and has significantly affected the entire cancer care team, including (but not limited to) oncologists, oncology nurses, oncology nurse navigators, surgical and clinical pathologists, and pharmacists.
The Oncology Nurse-APN/PA spoke with Salimah H. Meghani, PhD, MBE, RN, FAAN, a faculty member at the University of Pennsylvania School of Nursing, Philadelphia, about her various roles and thoughts on what is exciting in the field of palliative care.
The Academy of Oncology Nurse & Patient Navigators had a strong presence at the first of the Biden Cancer Initiative’s “Conversation with Dr Biden,” on March 10, 2018. These conversations provide members of the patient support network with the opportunity to share their perspectives on the cancer journey.
To sign up for our newsletter or print publications, please enter your contact information below.
